Most chronic fatigue, metabolic inflexibility, and slow recovery trace back to the same root cause: mitochondria that can't produce enough ATP. The Mito Stack addresses this at three levels — SS-31 repairs the physical membrane structure, MOTS-c retrains metabolic signaling to build new mitochondria, and NAD+ restores the redox currency both processes consume.
The practical case is strongest for two populations:
- Those experiencing GLP-1 fatigue (where rapid caloric deficit from semaglutide, tirzepatide, or retatrutide strains mitochondrial capacity)
- Individuals with chronic energy depletion from illness, overtraining, or age-related decline.
The protocol runs in 12-week cycles — SS-31 loads first to repair membrane integrity (with NAD+ layered in as support), then MOTS-c is added in to build capacity on a repaired foundation.
At a Glance
| Component | Core role |
|---|---|
| SS-31 | Repairs mitochondrial membranes, reducing electron leak and oxidative damage |
| MOTS-c | Retrains metabolic signaling — improves fuel flexibility and builds new mitochondria |
| NAD+ | Restores the redox currency cells need for energy production, DNA repair, and longevity enzymes |
| Protocol cadence | 12-week cycles with loading and maintenance phases |
| Primary applications | Fatigue, metabolic dysfunction, injury recovery support, and longevity support |
What Is a Mitochondrial Peptide Stack?
A mitochondrial peptide stack combines multiple compounds that target different aspects of mitochondrial function. Rather than relying on a single peptide, stacking addresses structure (SS-31), signaling (MOTS-c), and fuel (NAD+) simultaneously — the three axes that determine whether your mitochondria produce abundant energy or limp along in survival mode.
MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA gene. When released during exercise or metabolic stress, it travels to the nucleus to regulate gene expression — a process called retrograde mitochondrial signaling. This exercise-mimetic effect makes MOTS-c a cornerstone of mitochondrial optimization protocols.
SS-31 (Elamipretide) targets the structural foundation: cardiolipin in the inner membrane. NAD+ provides the redox currency both peptides require to function. The MOTS-c SS-31 stack, combined with NAD+, creates a complete system that repairs existing mitochondria while building new, metabolically intelligent copies.
The Three Axes of Mitochondrial Health
| Axis | Function | How It Fails | Result |
|---|---|---|---|
| Cardiolipin integrity | Anchors electron transport chain | Oxidized membranes leak electrons | Low ATP, high ROS, inflammation |
| Redox currency (NAD+) | Powers enzymes, activates sirtuins | Depleted by stress, aging, alcohol | Fatigue, DNA damage, metabolic rigidity |
| Adaptive signaling (AMPK → PGC-1α) | Drives mitochondrial biogenesis | Blunted by cortisol, nutrient overload | Slow recovery, weight gain |
Component 1: SS-31 — Membrane Repair
SS-31 (also called Elamipretide) is a tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane. Cardiolipin anchors the electron transport chain; when it oxidizes, electrons leak, ATP production drops, and reactive oxygen species (ROS) spike.
SS-31 stabilizes cardiolipin, tightening the respiratory chain so electrons flow cleanly instead of leaking as ROS — up to 60% reduction in preclinical models. The practical result: more ATP from each oxygen molecule, less oxidative damage, and rapid improvement in fatigue.
Phase 2 trials in Barth syndrome and cardiomyopathies confirm improved ATP kinetics and functional endpoints — SS-31 is FDA approved.
See SS-31 Peptide Guide for complete coverage.
Component 2: MOTS-c — Metabolic Reprogramming
MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA gene that acts as an exercise mimetic. It signals from mitochondria back to the nucleus, activating metabolic adaptation pathways — a process called retrograde signaling.
MOTS-c flips the same metabolic switch exercise does (AMPK activation), triggering new mitochondrial construction and shifting cells from glucose hoarding to flexible fuel use. Under metabolic stress, it travels to the nucleus to directly regulate gene expression related to glucose handling — a process called retrograde signaling. Endurance improves, metabolic rate stabilizes, and the body responds better to caloric deficits.
Published in Cell Metabolism (2015) by the Cohen Lab at USC, with follow-up studies confirming metabolic benefits in humans. Exercise increases circulating MOTS-c levels by up to 12-fold.
See MOTS-c Peptide Guide for more.
Component 3: NAD+ — Redox Currency
NAD+ is the central cofactor for energy metabolism, DNA repair, and sirtuin activation. Levels decline ~50% between age 20 and 50, and faster under chronic stress or inflammation.
NAD+ restores the redox ratio that sirtuins need to function (SIRT1–3 activation), calms the DNA-repair enzyme PARP from over-consuming cellular resources, and resynchronizes circadian rhythms. The downstream effect: sustained energy, better sleep, deeper recovery, improved mental clarity.
Multiple RCTs with NMN/NR precursors confirm tissue NAD+ elevation; IV/IM NAD+ provides higher peak levels.
See NAD+ Guide for a deep dive.
How the Components Work Together
The synergy matters more than any single component:
- SS-31 + NAD+: Efficient electron transport plus abundant redox fuel = higher ATP output without oxidative damage
- MOTS-c + NAD+: New mitochondria (from biogenesis) need charged batteries (NAD+) to function
- SS-31 + MOTS-c: Repair existing mitochondria while building new, metabolically intelligent copies
Once ATP production exceeds maintenance cost, cells stop triaging and start investing in repair: collagen renews, nerves fire cleanly, hormones regain sensitivity.
Protocol: 12-Week Mito Stack Cycle
| Phase | SS-31 | MOTS-c | NAD+ | Support |
|---|---|---|---|---|
| Weeks 1–2 (loading) | 10 mg daily × 5–7 days, then 3×/week | n/a | 200 mg 4-5×/week | Electrolytes, zone-2 cardio |
| Weeks 3–6 | 5-10 mg 3×/week | 5-10 mg 2×/week | 150–200 mg 3–5×/week | Resistance training, protein ≥1.6 g/kg |
| Weeks 7–12 | 5-10 mg 2–3×/week | 5–10 mg 2×/week | 100-150 mg 3–4×/week | Sleep 7–9 hours, glycine + collagen |
Cycling: 12 weeks on, 4 weeks off. Repeat twice yearly or maintain lighter cadence (SS-31 weekly, MOTS-c pulses, NAD+ 2–3×/week).
Need help preparing your peptides? See the Reconstitution Guide for step-by-step instructions.
Timeline of Effects
| Timeframe | Cellular changes | What you notice |
|---|---|---|
| Weeks 1–2 | SS-31 tightens ETC, ROS drops | Warm steady energy, less soreness |
| Weeks 3–4 | MOTS-c activates AMPK/PGC-1α | Cardio feels easier, cravings decrease |
| Weeks 5–8 | NAD+ + sirtuins repair DNA/membranes | Better sleep, clearer skin, mental sharpness |
| Weeks 9–12 | Mitochondrial density peaks | Resilience under stress, faster recovery |
Applications
GLP-1 Fatigue: The Mitochondrial Bottleneck
Fatigue is the most common complaint among people on GLP-1 medications. Semaglutide fatigue, tirzepatide fatigue, ozempic fatigue, mounjaro fatigue — different drug names, same pattern. Weight loss works, but energy crashes. The forums are full of people who hit a wall around month 2–3.
Why it happens: GLP-1 agonists shift metabolism rapidly toward fat oxidation. Fat burning is more mitochondrially demanding than glucose burning. When the instruction to increase oxidation arrives at mitochondria that were already running near capacity — because of age, chronic inflammation, or baseline depletion — they can't keep up. ATP production falters under the new demand.
Why the Mito Stack helps: The stack addresses all three failure points:
- SS-31 repairs the membrane structure so electrons flow cleanly (less waste, more output)
- MOTS-c signals cells to build more mitochondria and improve fuel selection (more capacity)
- NAD+ provides the redox currency both processes require (fuel for the machinery)
The result: mitochondria can actually execute what GLP-1s are asking for. Energy stabilizes, the "wall" retreats, and weight loss continues without the fatigue tax.
Practical integration: While not prescriptive, many practioners begin the Mito Stack 4–6 weeks of GLP-1 therapy, when fatigue becomes noticeable and blood plasma levels have stabilized. Starting MOTS-c at 5mg 2–3×/week and NAD+ support addresses the immediate bottleneck. SS-31 is added if fatigue persists or if recovery from exercise remains slow.
See Retatrutide + NAD+ Protocol for beginner implementation.
Injury recovery
The Mito-Stack provides the ATP foundation that tissue repair requires. It's typically used after vascular restoration (BPC-157/TB-500) when cellular energy becomes the limiting factor (typically after four weeks). See our injury recovery protocol for more detail.
Longevity and anti-aging
By sustaining sirtuin activity, supporting DNA repair, and maintaining mitochondrial density, the Mito-Stack addresses the metabolic decline that underlies aging.
Side Effects and Safety
SS-31: FDA approved for Barth's Syndrome (at much higher doses). Generally well tolerated.
MOTS-c: Fatigue may present if caloric needs are not addressed, especially alongisded GLP-1s. Eat adequately on training days.
NAD+: Slow injection rate to avoid flushing, diziness. Hydration is important.
Contraindications: Active malignancy, uncontrolled hypertension, acute infection — pause until resolved.
Monitoring: Consider baseline and month-2 checks for CMP, lipids, and hs-CRP.
FAQ
Can I run the Mito Stack without NAD+ injections?
You'll blunt the synergy. NAD+ is the currency the other peptides spend. Oral NMN/NR is an alternative but provides lower peak levels than injection.
How does The Mito Stack differ from NAD+ therapy alone?
NAD+ provides fuel but doesn't repair damaged membranes (SS-31's role) or stimulate new mitochondrial construction (MOTS-c's role). The full Mito Stack addresses root causes — structure, signaling, and fuel — rather than currency alone.
Is the Mito Stack anabolic?
Not directly muscle-building, but by improving ATP production and reducing inflammation, it makes training and any growth-hormone protocol more effective.
What is the best MOTS-c and SS-31 stack dosage?
Most protocols use MOTS-c 5–10 mg and SS-31 8-10 mg, administered 2–3 times weekly. The Mito Stack adds NAD+ 150–200 mg to complete the triad. See the Protocol section above for phase-specific dosing.
Can I take MOTS-c and SS-31 together on the same day?
Yes. These peptides work on different mitochondrial systems — SS-31 on membrane structure, MOTS-c on metabolic signaling — and do not compete for absorption. Many practitioners administer both in the same session alongside NAD+ infusion.
Related Topics
- NAD+ Guide — Complete NAD+ overview
- BPC-157 + TB-500 for Injury Recovery — Vascular restoration
- Retatrutide + NAD+ Protocol — GLP-1 with metabolic support
- SS-31 Guide — Elamipretide — Cardiolipin stabilizer at the core of the stack
- Peptide Stacking Guide — How the Mito Stack fits into the 5-axis stacking framework
- BPC-157 Guide — Vascular repair often needed before the Mito Stack is effective
- TB-500 Guide — Cellular mobility layer often preceding the Mito Stack
- Semaglutide Guide — GLP-1 agonist — The Mito Stack addresses its mitochondrial costs
- Tirzepatide Guide — Dual-agonist — The Mito Stack supports during therapy
- Circadian Reset Protocol — How NAD+/MOTS-c support the circadian clock through the SIRT1-CLOCK/BMAL1 axis
References
SS-31 (Elamipretide)
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. doi:10.1111/bph.12461
- Phase 2 trials in Barth syndrome and cardiomyopathies demonstrate improved ATP kinetics and functional endpoints
MOTS-c
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metab. 2018;28(3):516-524. doi:10.1016/j.cmet.2018.06.008
NAD+
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. doi:10.1016/j.cmet.2018.02.011
- Multiple RCTs with NMN/NR precursors demonstrate tissue NAD+ elevation and functional improvements
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.